Form 4: Dyne Therapeutics' Chief Scientific Officer Sells Shares to Cover Tax Obligations

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On August 19, 2024, Oxana Beskrovnaya, the Chief Scientific Officer of Dyne Therapeutics, sold 2,340 shares of common stock at a weighted average price of $45.01 and 296 shares at a weighted average price of $46.
• These sales were executed to satisfy tax withholding obligations related to the vesting of restricted stock units granted on November 15, 2023.
• The sales were conducted under a pre-arranged plan (Rule 10b5-1) established on January 25, 2024.
• Following the transactions, Beskrovnaya directly owns 144,875 shares of Dyne Therapeutics, which includes 119,668 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions for tax purposes and doesn't necessarily indicate a change in the insider's confidence in the company.

Positives

• The sales were conducted under a pre-arranged plan (Rule 10b5-1), indicating they were not based on current insider information.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small number of shares involved.

Key Dates